X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TPT0701 is a CB1 receptor antagonist, which offers a novel approach to appetite suppression aiming to provide individuals with a safe and effective means to manage their cravings. It is being evaluated in preclinical studies for the treatment of obesity.
Lead Product(s): TPT0701
Therapeutic Area: Nutrition and Weight Loss Product Name: TPT0701
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2024
Details:
Company is launching its first product, XATEPA®, on the German market. XATEPA® is based on cannabinoids, being indiacated for the treament of neuropathic pain, sclerosis and mental health disorders.
Lead Product(s): Cannabinoid
Therapeutic Area: Neurology Product Name: Xatepa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
Tetra Pharm Technologies will use the net proceeds to increase its capacity in Research and Development and expand its commercial operations internationally.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $9.7 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 26, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
